Adbry targets the cytokine IL-13, which drives inflammatory processes of symptoms commonly seen in atopic dermatitis. Credit: Pormezz / Shutterstock.

Leo Pharma has announced that its injection treatment for atopic dermatitis, Adbry (tralokinumab-ldrm), will gain an alternative mode of administration following a US Food and Drug Administration (FDA) approval for its single-dose autoinjector.

Adbry targets interleukin-13 (IL-13), a cytokine that drives inflammatory processes associated with the symptoms of atopic dermatitis. Adbry is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies, following a December 2021 approval.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

According to GlobalData’s consensus forecasts, Adbry is expected to generate global sales of $1.3bn in 2030. The treatment produced net global sales of $106m in 2023. GlobalData is the parent company of Pharmaceutical Technology.

As per the 13 June press announcement, the treatment will now be available for adult patients as a 300 mg/2 mL single dose autoinjector treatment as another option to the existing 150 mg/1 mL pre-filled injectable, which will continue to be available in the US. Leo Pharma is taking steps to make the newly approved device available to US patients in the coming months, EVP and President, Region North America at Leo Pharma, Brian Hilberdink said in the press release.

“We understand that no patient is the same, and through this extended approval we have taken a positive step forward to equip those living with atopic dermatitis with more choices,” said Shannon Schneider, Senior Medical Affairs Director at LEO Pharma. 

Ballerup, Denmark-based LEO is not the only pharma making strides in the atopic dermatitis space. As per a GlobalData report, the atopic dermatitis market is predicted to be worth $24.4bn across the 61 geographical markets in 2030, with 71.8% of that coming from the seven major markets of US, France, Germany, Italy, Spain, UK, and Japan.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier in the week, Denmark-based Union Therapeutics shared positive data from its Phase IIb ADESOS study (NCT05469464) which evaluated orismilast as an oral treatment for moderate- to-severe atopic dermatitis. Union is looking to initiate a Phase III programme and has reached out to the FDA with initial plans.

Also in the picture is Dermavant’s nonsteroidal topical nonsteroidal, VTAMA (tapinarof), which received FDA acceptance for its supplemental New Drug Application (sNDA). According to GlobalData’s analysts, atopic dermatitis  presents a mine of opportunities, particularly for drugs that target AhR due to the low rate of adverse effects seen in previous clinical trials.